Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

Department of Cancer and Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, USA.
Breast Cancer Research and Treatment (Impact Factor: 3.94). 03/2010; 124(2):433-9. DOI: 10.1007/s10549-010-0840-0
Source: PubMed


To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3-4 neutropenia (OR = 0.52, 95% CI = 0.29-0.92) but had worse DFS (HR = 1.59, 95% CI = 0.99-2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.

Download full-text


Available from: William E Barlow,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacogenetic research has the potential to identify appropriate individualized therapeutic regimens based upon a patient’s genetic makeup. Numerous genetic variants that may modify the effects of drugs commonly used to treat breast cancer have been examined; however, current evidence is insufficient to support the clinical utility of any of these markers. Recent research in breast cancer pharmacogenetics has included genes in drug metabolism, oxidative stress, DNA repair, and other pathways, and outcome after breast cancer chemotherapy. Studies have also addressed the basis for taxane-induced neurotoxicity and aromatase inhibitor-induced musculoskeletal symptoms. For tamoxifen, despite promising results from previous studies for a role of CYP2D6 genotypes in predicting breast cancer recurrence, data from two prospective randomized trials have not supported these findings. Genome-wide approaches based on large prospective randomized trials have the potential to greatly elucidate the genomic basis for optimizing drug efficacy and reducing toxicity.
    Current Breast Cancer Reports 12/2012; 4(4). DOI:10.1007/s12609-012-0088-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are no established genetic markers for prediction of outcomes after cyclophosphamide (CP)-containing adjuvant therapy for breast cancer. In an ancillary study to a SWOG (Southwest Oncology Group) trial (S8897), we investigated functional polymorphisms in 4 genes in CP pharmacokinetic pathways in relation to hematologic toxicity and disease-free survival (DFS). Germline DNA was available from 458 women who were at high risk of relapse and was randomized to CAF (CP, intravenous doxorubicin, and 5-fluorouracil) versus CMF (CP, intravenous methotrexate, and 5-fluorouracil) ± tamoxifen, and from 874 women who had a presumed favorable prognosis and did not receive adjuvant therapy. Odds ratios for grade 3 and 4 hematologic toxicity in the treated group and hazard ratios for DFS associated with selected functional polymorphisms in CYP2B6CYP3A4GSTA1 and GSTP1 were estimated by logistic regression and Cox proportional hazard regression. Compared with women with AA genotypes, those with at least 1 GSTP1 variant G allele had reduced risk of grade 3 and 4 neutropenia [odds ratios (OR) = 0.63, 95% CI = 0.41-0.97] and leucopenia (OR = 0.59, 95% CI = 0.39-0.89). No other associations between single nucleotide polymorphisms and toxicity or survival were found in the treated or untreated group. Known genetic variants in genes involved in CP pharmacokinetics may not have major effects on DFS in breast cancer patients. The lower risk of developing high-grade hematologic toxicity among women with variant GSTP1 alleles suggests that genetic markers in combination with clinical factors may be useful in defining a subgroup of women who are less susceptible to adverse hematologic toxicities with CP-containing therapies.
    Clinical Cancer Research 12/2010; 16(24):6169-76. DOI:10.1158/1078-0432.CCR-10-0281 · 8.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mitochondrion is vital for many metabolic pathways in the cell, contributing all or important constituent enzymes for diverse functions such as β-oxidation of fatty acids, the urea cycle, the citric acid cycle, and ATP synthesis. The mitochondrion is also a major site of reactive oxygen species (ROS) production in the cell. Aberrant production of mitochondrial ROS can have dramatic effects on cellular function, in part, due to oxidative modification of key metabolic proteins localized in the mitochondrion. The cell is equipped with myriad antioxidant enzyme systems to combat deleterious ROS production in mitochondria, with the mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD) acting as the chief ROS scavenging enzyme in the cell. Factors that affect the expression and/or the activity of MnSOD, resulting in diminished antioxidant capacity of the cell, can have extraordinary consequences on the overall health of the cell by altering mitochondrial metabolic function, leading to the development and progression of numerous diseases. A better understanding of the mechanisms by which MnSOD protects cells from the harmful effects of overproduction of ROS, in particular, the effects of ROS on mitochondrial metabolic enzymes, may contribute to the development of novel treatments for various diseases in which ROS are an important component.
    International Journal of Molecular Sciences 12/2011; 12(10):7114-62. DOI:10.3390/ijms12107114 · 2.86 Impact Factor
Show more